You are here

Commercial Availability for Lunesta Delayed

MARLBOROUGH, Mass., Jan. 11 /PRNewswire-FirstCall/ -- Sepracor Inc. (NASDAQ:SEPR) today announced a revision to the anticipated commercial availability of LUNESTA(TM) brand eszopiclone for the treatment of insomnia.

On December 15, 2004, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for LUNESTA for the treatment of insomnia. As expected, the FDA recommended that LUNESTA, like all other non-benzodiazepine hypnotics, be classified as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA).

The Federal government's administrative process for formally classifying LUNESTA as a Schedule IV controlled substance is not yet complete. Because of uncertainties regarding marketing the product prior to completion of scheduling, Sepracor's plan to make LUNESTA commercially available in early January 2005 is no longer feasible. Sepracor is currently working diligently with the FDA and DEA to resolve these uncertainties and conclude final administrative actions related to the scheduling of LUNESTA.

At this time, Sepracor anticipates that LUNESTA will be available to patients nationwide within the first quarter of 2005.

"All commercial activities, including manufacturing, supply chain and sales and marketing required for a successful launch, are firmly in place," said W. James O'Shea, President and Chief Operating Officer at Sepracor.

Source: Sepracor Inc.

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers